You are here: Industry Insights > Novartis

News List

Novartis firm AveXis gets EC nod for Zolgensma to treat spinal muscular atrophy pharmaceutical-business-review
May 21, 2020
Novartis company AveXis has secured conditional approval from the European Commission (EC) for its Zolgensma (onasemnogene abeparvovec) to treat spinal muscular atrophy (SMA).
Novartis’ AveXis gets EC conditional approval for Zolgensma pharmaceutical-technology
May 20, 2020
Novartis subsidiary AveXis has received conditional approval from the European Commission (EC) for Zolgensma (onasemnogene abeparvovec) to treat spinal muscular atrophy (SMA).
Dyno Therapeutics launches with deals from Novartis and Sarepta pharmaceutical-technology
May 13, 2020
Biotechnology company Dyno Therapeutics has launched from stealth mode with focus on using artificial intelligence (AI) technology to develop adeno-Associated Virus (AAV) vectors.
Novartis gets FDA nod for Tabrecta to treat metastatic NSCLC with METex14 pharmaceutical-business-review
May 11, 2020
Novartis has secured approval from the US Food and Drug Administration (FDA) for its Tabrecta (capmatinib) to treat adult patients metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping (METex14).
Novartis Receives CHMP Positive Opinion for Enerzair® Breezhaler americanpharmaceuticalreview
May 07, 2020
Novartis announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion.
Speedy US approval for Novartis' Tabrecta pharmatimes
May 07, 2020
Novartis' Tabrecta (capmatinib, formerly INC280) has been awarded accelerated approval by the US Food and Drug Administration for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have a mutation that leads to MET ex
Novartis receives CHMP positive opinion for Enerzair Breezhaler pharmaceutical-business-review
May 06, 2020
Novartis announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion.
CHMP puts eight new medicines forward for approval pharmatimes
May 06, 2020
The European Medicines Agency's human medicines committee (CHMP) has put forward eight medicines for approval at its April meeting.
Cosentyx Gains Fourth indication in EU for Axial Spondyloarthritis Spectrum americanpharmaceuticalreview
May 05, 2020
Novartis announced the European Commission (EC) has approved Cosentyx® (secukinumab) for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA).
Novartis Releases Q1 Results, Updates COVID-19 Global Response americanpharmaceuticalreview
May 04, 2020
Novartis reported net income increased 34% to $3.55 billion in Q1 2020. Sales increased 13% to $12.3 billion. Key growth drivers included Entresto, Zolgensma, Kisqali, and Piqray.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page